[ 177 Lu]-Psma-617 Radionuclide Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer – Author's Reply

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(18)30534-5
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer With 177 Lu-Psma-617

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

225Ac-Psma-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Dosimetry of Lu-177 PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pre-Therapeutic Imaging and “Whole Body” Tumor Dosimetry With Treatment Outcomes

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Targeted Α-Therapy of Metastatic Castration-Resistant Prostate Cancer With225Ac-Psma-617: Dosimetry Estimate and Empiric Dose Finding

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2012English

Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ( 177 Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

Oncologist
Cancer ResearchMedicineOncology
2020English

Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancer Journal
Cancer ResearchOncology
2016English

Clinical Outcome of Standardized 177Lu-Psma-617 Therapy in Metastatic Prostate Cancer Patients Receiving 7400 MBq Every 4 Weeks

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy